Using Electronic Health Care Records for Drug Safety Signal Detection
Medical CarePublished 28 August 2012Open access
Martijn J. Schuemie, Preciosa M. Coloma, Huub Straatman, Ron M. C. Herings, Gianluca Trifirò, J. Matthews
Citations84
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Combinations of methods demonstrate good performance in distinguishing known ADRs from negative controls, and it is assumed that these could also be used to detect new drug safety signals.
Abstract
Combinations of methods demonstrate good performance in distinguishing known ADRs from negative controls, and we assume that these could also be used to detect new drug safety signals.
Keywords
Economics, Econometrics and FinancePharmacology, Toxicology and Pharmaceutics
Bayesian AnalysisPrior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper)
3,996 Citations2006Andrew Gelman
Drug SafetyUnder-Reporting of Adverse Drug Reactions
1,817 Citations2006Lorna Hazell, Saad Shakir
Evidence of significant and widespread under-reporting of ADRs to spontaneous reporting systems including serious or severe ADRs is provided.
Pharmacoepidemiology and Drug SafetyUse of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
1,730 Citations2001Stephen Evans, Patrick Waller +1 more
The process of generating ‘signals’ of possible unrecognized hazards from spontaneous adverse drug reaction reporting data has been likened to looking for a needle in a haystack but statistical approaches to the data have been underutilised.
Econstor (Econstor)Prior distributions for variance parameters in hierarchical models
1,559 Citations2004Andrew Gelman
Pharmacoepidemiology and Drug SafetyThe reporting odds ratio and its advantages over the proportional reporting ratio
1,059 Citations2004Kenneth J. Rothman, Stephan Lanes +1 more
This paper reviews the problem with the proportional reporting ratio (PRR) and shows how the corresponding odds ratio represents an improvement over the PRR.
The American StatisticianBayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System
770 Citations1999William DuMouchel
Here, a baseline or null hypothesis expected frequency is constructed for each cell, and screening criteria for ranking the cell deviations of observed from expected count are suggested and compared.
American Journal of EpidemiologyPerformance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies using Claims Data
712 Citations2001Sebastian Schneeweiß
The authors compared the predictive performance of comorbidity scores for use in epidemiologic research with administrative databases and found that number of distinct medications used was the best predictor of future physician visits and a good predictor of mortality.
Statistics in MedicineTutorial in biostatistics: the self‐controlled case series method
712 Citations2005Heather Whitaker, Paddy Farrington +2 more
The origins, assumptions, limitations, and uses of the self‐controlled case series method are described and the rationale for the model and the derivation of the likelihood are explained in detail using a worked example on vaccine safety.
Drug SafetyDeterminants of Under-Reporting of Adverse Drug Reactions
555 Citations2009Elena Lopez-Gonzalez, María Teresa Herdeiro +1 more
While personal and professional factors display a weak influence, the knowledge and attitudes of health professionals appear to be strongly related with reporting in a high proportion of studies, which may have important implications in terms of public health.
Pharmacoepidemiology and Drug SafetyCombining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project
261 Citations2010Preciosa M. Coloma, Martijn J. Schuemie +10 more
The framework, process, and preliminary results of combining data from European electronic healthcare record (EHR) databases for large‐scale monitoring of drug safety are described.
British Journal of Clinical PharmacologyAttitudinal survey of voluntary reporting of adverse drug reactions
258 Citations1999Eland, Belton +4 more
There is a considerable degree of underreporting of ADRs, which might partly be explained by lack of knowledge and misconceptions about spontaneous reporting of adverse drug reactions.
Journal of General Internal MedicineAdverse drug event monitoring at the food and drug administration
245 Citations2003Syed Rizwanuddin Ahmad
The FDA is strengthening its postmarketing surveillance with access to new data sources that have the potential to further improve the identification, quantification, and subsequent management of drug risk.
Drug SafetyCausal or Casual?
241 Citations1997Ronald H.B. Meyboom, Yechiel A. Hekster +3 more
It may be recommended to restrict case-causality assessment to selected case reports that are likely to play an active role in pharmacovigilance and to use specific systems, adapted to the reaction or problem involved.
European Journal of Clinical PharmacologyUnder-reporting of adverse drug reactions
239 Citations1998Ana Alvarez-Requejo, Alfonso Carvajal +4 more
The under-reporting rate of ADRs is considerable, though not homogeneous for the different cases, and should be taken into account when comparing adverse effects (AEs) for different drugs.
Drug SafetyPrinciples of Signal Detection in Pharmacovigilance
233 Citations1997Ronald H.B. Meyboom, Toine C. G. Egberts +4 more
A proposal is made for a standard signal management procedure at pharmacovigilance centres, including the following steps: signal delineation, literature search, preliminary inventory of data, collection of additional information, consultation with the World Health Organization Centre for International Drug Monitoring and the relevant drug companies, aggregated data assessment and a report in writing.
European Journal of Clinical PharmacologyAttitude survey of adverse drug-reaction reporting by health care professionals across the European Union
194 Citations1997Karen J. Belton
The results of this survey demonstrate some of the advantages and disadvantages of transnational, multilingual studies of this type, but indicate that there is scope for the further development of such techniques and their use on a wider basis in the EU and elsewhere.
Statistics in MedicineExtending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events
191 Citations2005G. Niklas Norén, Andrew Bate +2 more
More accurate credibility interval estimates are proposed and a Mantel–Haenszel‐type adjustment is proposed to control for suspected confounders in the WHO international drug safety database.
Drug SafetyThe Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts
181 Citations1998Sten Olsson
The rationale for setting up the WHO International Programme for Adverse Reaction Monitoring, 30 years ago was to make it possible to identify rare adverse drug reactions that could not be found through clinical trial programmes, and the scope of the programme has expanded over time to accommodate the expansion of the field of drug safety monitoring.
BiometricsAccounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model
163 Citations2004Scott Berry, Donald A. Berry
This work proposes a three‐level hierarchical mixed model of adverse events that allows for borrowing across body systems, but there is greater potential—depending on the actual data—for borrowing within each body system.
Pharmacoepidemiology and Drug SafetyMethods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD
91 Citations2010Martijn J. Schuemie
A sequential set of methods for detecting and filtering drug safety signals in longitudinal databases is presented.
New England Journal of MedicineDrug Safety Reform at the FDA — Pendulum Swing or Systematic Improvement?
80 Citations2007Mark McClellan
Jerry Avorn and Mark McClellan debate the reauthorization of the Prescription Drug User Fee Act, the effect of user fees on drug safety, and ways of improving post-marketing surveillance.
PubMedAcute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature.
70 Citations1989Robert Hootkins, Andrew Z. Fenves +1 more
It is concluded that oral ciprofloxacin therapy may lead to acute renal failure secondary to tubulointerstitial nephritis characterized by an increased creatinine to BUN ratio.
Pharmacoepidemiology and Drug SafetyThe lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals
65 Citations2011Mariley Pérez García, Albert Figueras
Underreporting suspected adverse drug reactions (ADRs) is one of the main problems that face the pharmacovigilance (PhV) systems based on yellow card schemes.
Archives of Internal MedicineAcute Renal Failure Due to Ciprofloxacin
57 Citations1990Michael Allon
Renal function should be closely monitored in patients receiving ciprofloxacin therapy, especially if other potentially nephrotoxic drugs are prescribed concomitantly.
British Journal of Clinical PharmacologyNon‐sedating antihistamine drugs and cardiac arrhythmias – biased risk estimates from spontaneous reporting systems?
53 Citations2002Marie L. De Bruin, Eugène van Puijenbroek +3 more
The data suggest that non-sedating antihistamines might have an increased risk for inducing arrhythmia, and strongly suggest that the increased risk identified can at least partly be explained by reporting bias as a result of publications about and mass media attention for antihistamine induced arrhythmias.
Peritoneal Dialysis InternationalVancomycin and Ciprofloxacin: Systemic Antibiotic Administration for Peritoneal Dialysis-Associated Peritonitis
47 Citations2004Éric Goffin, Laurence Herbiet +6 more
In the authors' opinion, vancomycin should still be used for gram-positive infections because of its high susceptibility rate compared with first-generation cephalosporins, providing a close monitoring of the local epidemiology.
European Journal of Clinical PharmacologyDrug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature
43 Citations1997Jan Paul Ottervanger, J.H.P. Wilson +1 more
Pharmacoepidemiology and Drug SafetyUnderreporting of recognized adverse drug reactions by primary care physicians: an exploratory study
40 Citations2011Francisca González‐Rubio, Amaia Calderón‐Larrañaga +4 more
The magnitude of underreporting of adverse drug reactions is evaluated and possible reporting patterns according to patient characteristics and the type of reaction are investigated based on the integration of information obtained from primary care electronic medical records and the Spanish Pharmacovigilance System.
Medical CarePrivacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics
37 Citations2010Jeremy A. Rassen, Daniel H. Solomon +3 more
The PS-based pooling method offered strong protection of patient privacy and a reasonable balance between analytic integrity and flexibility of study execution and would recommend its use in other studies that require pooling of databases, multivariate adjustment, and privacy protection.
Postgraduate MedicineImproving the Reporting of Adverse Drug Reactions in the Hospital Setting
36 Citations2010Richard Pushkin, Lynda Frassetto +3 more
The present system for addressing adverse events, obstacles to reporting them, and the important role any hospital physician could play in reporting adverse events and potential adverse drug reactions are described.
Challenges for the FDA: The Future of Drug Safety: Workshop Summary
10 Citations2007Leslie Pray, Sally Robinson
Challenges for the FDA: The Future of Drug Safety, Workshop Summary explains the presentations and discussions in seven key areas: addressing the FDA's resource challenges; strengthening the scientific base of the agency; integrating pre- and postmarket review; enhancing postmarket safety monitoring; conducting confirmatory drug safety and efficacy studies; enhancing the value of clinical trial registration; and enhancing the FAA's postmarket regulation and enforcement.